Use of an [18F]setoperone bolus + infusion protocol to delineate age related reduction in 5HT2A receptor binding potential in female rhesus monkeys

2005 ◽  
Vol 25 (1_suppl) ◽  
pp. S652-S652
Author(s):  
Wai-Si Eng ◽  
Stephen Krause ◽  
Christine Ryan ◽  
Holly Sleph ◽  
Maria Michener ◽  
...  
1999 ◽  
Vol 19 (2) ◽  
pp. 218-229 ◽  
Author(s):  
Evan D. Morris ◽  
Svetlana I. Chefer ◽  
Mark A. Lane ◽  
Raymond F. Muzic ◽  
Dean F. Wong ◽  
...  

The relation between striatal dopamine D2 receptor binding and aging was investigated in rhesus monkeys with PET. Monkeys (n = 18, 39 to 360 months of age) were scanned with 11C-raclopride; binding potential in the striatum was estimated graphically. Because our magnetic resonance imaging analysis revealed a concomitant relation between size of striatum and age, the dynamic positron emission tomography (PET) data were corrected for possible partial volume (PV) artifacts before parameter estimation. The age-related decline in binding potential was 1% per year and was smaller than the apparent effect if the age-related change in size was ignored. This is the first in vivo demonstration of a decline in dopamine receptor binding in nonhuman primates. The rate of decline in binding potential is consistent with in vitro findings in monkeys but smaller than what has been measured previously in humans using PET. Previous PET studies in humans, however, have not corrected for PV error, although a decline in striatal size with age has been demonstrated. The results of this study suggest that PV correction must be applied to PET data to accurately detect small changes in receptor binding that may occur in parallel with structural changes in the brain.


Bone ◽  
2001 ◽  
Vol 28 (3) ◽  
pp. 295-302 ◽  
Author(s):  
A Black ◽  
E.M Tilmont ◽  
A.M Handy ◽  
W.W Scott ◽  
S.A Shapses ◽  
...  

2012 ◽  
Vol 10 (2) ◽  
pp. 20-27
Author(s):  
Nadezda Dmitrievna Goncharova ◽  
Viktor Yuryevich Marenin ◽  
Arsen Arsenovich Vengerin ◽  
Alla Vyacheslavovna Shmaliy

We have investigated age-related changes in the activity of antioxidant enzyme system and intensity of lipid peroxidation in erythrocytes of young and old female rhesus monkeys with depression-like and standard behavior. Revealed significant disturbances in the activities of GR and GSH-Px in monkeys with depression-like behavior are accompanied more pronounced age-related decrease in reliability of antioxidant enzyme defense and development of oxidative stress.


2018 ◽  
Author(s):  
Kendra L. Seaman ◽  
Christopher T. Smith ◽  
Eric J. Juarez ◽  
Linh C. Dang ◽  
Jaime J. Castrellon ◽  
...  

AbstractTheories of adult brain development, based on neuropsychological test results and structural neuroimaging, suggest differential rates of age-related change in function across cortical and subcortical sub-regions. However, it remains unclear if these trends also extend to the aging dopamine system. Here we examined cross-sectional adult age differences in estimates of D2-like receptor binding potential across several cortical and subcortical brain regions using PET imaging and the radiotracer [18F]fallypride in two samples of healthy human adults (combined N = 132). After accounting for regional differences in overall radioligand binding, estimated percent difference in receptor binding potential by decade (linear effects) were highest in most temporal and frontal cortical regions (∼6–16% per decade), moderate in parahippocampal gyrus, pregenual frontal cortex, fusiform gyrus, caudate, putamen, thalamus, and amygdala (∼3–5%), and weakest in subcallosal frontal cortex, ventral striatum, pallidum, and hippocampus (∼0–2%). Some regions showed linear effects of age while many showed curvilinear effects such that binding potential declined from young adulthood to middle age and then was relatively stable until old age. Overall, these data indicate that the rate and pattern of decline in D2 receptor availability is regionally heterogeneous. However, the differences across regions were challenging to organize within existing theories of brain development and did not show the same pattern of regional change that has been observed in gray matter volume, white matter integrity, or cognitive performance. This variation suggests that existing theories of adult brain development may need to be modified to better account for the spatial dynamics of dopaminergic system aging.


2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 131-132
Author(s):  
Ricki Colman ◽  
Tamara Tchkonia ◽  
Tamar Pirtskhalava ◽  
Nino Giorgadze ◽  
Larissa Prata ◽  
...  

Abstract Aging is the biggest risk factor for the most serious chronic diseases and disabilities. Cellular senescence, a state in which cells stop dividing but release factors that damage other cells, may contribute to both age-related and chronic diseases. Removal of senescent cells from aged mice has been shown to delay aging and age–related disabilities. Our goal was to determine the ability of potential senolytic agents to remove senescent cells in a primate model. Several agents and combinations were tested including Fisetin, Navitoclax, combined Dasatinib and Quercetin, and combined Dasatinib and Fisetin. Here we describe the Dasatinib and Fisetin trial. Dasatinib is an FDA approved oral anticancer drug that has been used to treat chronic myelogenous leukemia in humans. Fisetin is a flavonoid that can be found in many plants, particularly strawberries, and acts as a coloring agent. After baseline measurements, six older (mean age=21 years) female rhesus monkeys (Macaca mulatta) were given a combined oral dose of Dasatinib (5 mg/kg) and Fisetin (100 mg/kg) on two consecutive days. Animals were additionally assessed at 1- and 7-weeks following dosing. At 7 weeks post dosing, there were fewer (p<0.05) p16+ cells in the epidermis compared to baseline. Similarly, there was a reduction (p<0.05) in p21+ cells in the epidermis at 1- and 7-weeks post dosing compared to baseline. There were no negative outcomes associated with treatment. This study provides preliminary evidence for the senolytic potential of combined Dasatinib and Fisetin treatment and indicates that pharmacological mitigation of age-related changes is possible.


2008 ◽  
Vol 37 (5) ◽  
pp. 229-238 ◽  
Author(s):  
Nadezhda D. Goncharova ◽  
Alla V. Shmaliy ◽  
Victor Y. Marenin ◽  
Sophia A. Smelkova ◽  
Boris A. Lapin

Sign in / Sign up

Export Citation Format

Share Document